By Pete McGinnis (Townhall)
We all know how important transparency is in a representative democracy like ours. And unfortunately, we can all point to plenty of failures of transparency: secretive international agreements, lawmakers with a preternatural ability to sell stocks at exactly the right time, and – most recently – the health and fitness of the U.S. commander-in-chief.
But here’s one you probably have never thought about: the lack of transparency from the Biden-Harris FDA and its Center for Tobacco Products. As the harm-reduction market booms with new options, the FDA has been reluctant to shoot it straight with the public and mom-and-pop stores on which products can be sold and which cannot.